Dyve Biosciences announced today that Tatyana Beldock joined the company’s board of directors.
Camarillo, California-based Dyve develops the DMAX delivery platform. Its transdermal drug delivery technology directly targets the acidic microenvironments that drive cancer cell growth and inflammation.
“We are thrilled to have Tatyana join our board,” said Dr. Ryan Beal, CEO of Dyve. “Tatyana brings a wealth of business, investment, and strategic experience to our team. I look forward to working side-by-side with her as we advance our immunology and oncology assets through the clinics and expand our strategic partnerships.”
Beldock brings with her more than 25 years of operating and financial experience in healthcare. Her track record covers fueling growth, advancing technology and increasing shareholder value. She spent time in biopharmaceuticals, health technology, medical devices and financials.
Among previous employers are Johnson & Johnson, Pfizer, J.P. Morgan and Citigroup, as well as a number of startups. Beldock currently serves as founder and managing partner at FireRock Advisors.
“Joining the Dyve Board of Directors is a wonderful opportunity to contribute to developing multiple breakthrough therapies for patients,” said Beldock. “Dyve’s platform science has shown tremendous potential in treating immuno-inflammatory and oncologic diseases. I’m excited to join the talented group of Dyve board directors and participate in this important work.”
